Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Shares Jumped Today

By Keith Speights – Jun 17, 2020 at 3:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The addition of a new executive underscored just how much the biotech is on the move.

What happened

Shares of Novavax (NVAX -1.26%) were jumping 5.8% as of 3:13 p.m. EDT on Wednesday after rising as much as 11.9% earlier in the day. The biotech announced the hiring of two new senior executives:  Senior Vice President and Chief Medical Officer Filip Dubovsky and Senior Vice President, Investor Relations and Corporate Affairs Silvia Taylor. But the primary factor driving shares higher was more likely growing anticipation among investors that Novavax would achieve success with its COVID-19 vaccine candidate NVX-CoV2373 and flu vaccine candidate NanoFlu.

So what

Biotech stocks typically don't move much because of new hires, except at the CEO level. It's not likely that either of Novavax's additions to its executive team served as a big catalyst today. However, the company's hiring of Filip Dubovsky does reinforce an underlying perception that Novavax is on its way to becoming a bigger player in the biopharmaceutical industry.

Scientist looking through a microscope

Image source: Getty Images.

Novavax poached Dubovsky from AstraZeneca (AZN 0.09%), where he served as head of clinical engagement and policy and deputy chief medical officer for clinical affairs. He previously led the clinical development of infectious-disease and vaccine programs at the big drugmaker. Landing a scientist with Dubovsky's credentials was a nice win for Novavax.

The addition of Dubovsky, though, is just the latest of several developments in recent months that reflect Novavax's rising prospects. In particular, the company's COVID-19 vaccine candidate attracted a $388 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) and a $60 million contract with the U.S. Department of Defense

Now what

There are two key things for investors to watch now with Novavax. The company expects to report results from its phase 1 clinical study of NVX-CoV2373 in July. If all goes well, it will advance the COVID-19 vaccine candidate into phase 2 testing. Novavax is also preparing to file for U.S. approval of NanoFlu but hasn't provided a specific date for when the filing is expected.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$17.97 (-1.26%) $0.23
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.89 (0.09%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.